1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

06 Mar 2024
Admin
News Article

Cynata Therapeutics Treated First Patient with CYP-001

Cynata Therapeutics announces first patient treated in phase 2 trial of CYP-001 in high-risk aGvHD

Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, confirms that the first patient has been enrolled and treated in its phase 2 clinical trial of CYP-001 in high-risk acute graft versus host disease (aGvHD).

CYP-001

CYP-001 is Cynata’s Cymerus off-the-shelf iPSC1 -derived MSC2 product candidate for intravenous infusion, which previously generated very encouraging safety and efficacy results in a phase 1 clinical trial in steroidresistant aGvHD.
The US FDA has cleared an Investigational New Drug (IND) application for CYP-001 and granted the product Orphan Drug Designation4 for the treatment of aGvHD.

About aGvHD

aGvHD is a potentially life-threatening complication of bone marrow transplants or similar procedures.
It arises when immune cells in the transplant (the graft) attack the recipient’s tissues (the host) as “foreign”.
In this trial, CYP-001 is being investigated as a potential immune modulating treatment for aGvHD.

Phase 2 Trial

This global phase 2 trial aims to enrol approximately 60 patients with high-risk aGvHD, who will be randomised to receive either steroids plus CYP-001, or steroids plus placebo.
The trial has been approved to commence in Australia, the USA and Turkey, and numerous clinical centres across those jurisdictions are now open for recruitment.
The first patient was enrolled in the USA.

Satement from CEO

Dr Kilian Kelly, Cynata’s chief executive officer, said: “The treatment of the first patient in this phase 2 trial marks a milestone moment in the clinical development journey of CYP-001 for aGVHD. We are continuing to open additional clinical centres, and we anticipate completion of enrolment by the end of this calendar year, with primary results available in the second half of 2025.”

About Cynata Therapeutics

Cynata Therapeutics Limited is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus, a proprietary therapeutic stem cell platform technology.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!